A pearl white vase slowly filling with golden light among glowing jellyfish in a deep teal sea.

Cagrilintide Dosage: Every Amount Studied, and What Is Only Repeated Online

November 2, 2026

Cagrilintide does not have a dose. It has trial arms, plus a pile of numbers that get copied from site to site. This guide lists every amount Novo Nordisk has tested in people, shows what each one did, and sorts the gray-market figures into the ones with a source and the ones without.

Ask PeptideBlog about any peptide

Quick answer: Cagrilintide has no approved dose anywhere. The published human amounts all come from Novo Nordisk trials. The phase 2 weight-loss trial tested 0.3, 0.6, 1.2, 2.4 and 4.5 mg once weekly by subcutaneous injection for 26 weeks, and the 4.5 mg group lost the most, 10.8% of body weight on the trial product estimand.[1] The amount carried into the combination drug CagriSema, and into the cagrilintide-alone arm of REDEFINE 1, is 2.4 mg once weekly.[2] The 5 mg and 10 mg vials sold as research chemicals, and the weekly ranges quoted on community sites, are not clinical dosing. Most of those ranges trace to no cagrilintide trial.

Figures in this section summarize amounts and schedules reported in published research, registered trials, or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

A pearl white vase slowly filling with golden light among glowing jellyfish in a deep teal sea.

Cagrilintide dosage chart: every studied amount at a glance

Cagrilintide is a lab-made, long-acting copy of amylin, a hormone the pancreas releases with insulin after meals. Amylin slows stomach emptying and signals fullness.[3] Novo Nordisk made a lipidated version, meaning a fatty-acid chain is attached, so one injection lasts about a week.[4] The EloralintideResearch amylin explainer covers the biology and the cagrilintide research entry covers identity and mechanism. This page covers the numbers.

Two terms first. An estimand is the exact question a trial analysis answers. The trial product (or efficacy) estimand asks what happens if everyone keeps taking the drug as assigned. The treatment policy estimand asks what happens to everyone randomized, whether or not they stayed on treatment. For active drugs the first is usually the bigger number, and both appear below with labels. A CagriSema arm means cagrilintide and semaglutide together, written as cagrilintide mg / semaglutide mg, so 2.4/2.4 is 2.4 mg of each.

Swipe the table sideways to see every column.

Amounts of cagrilintide studied or reported, by source
Trial or sourcePopulationRouteAmountFrequencyDurationEvidence category
Phase 1b with semaglutide (NCT03600480)96 adults, BMI 27.0 to 39.9, otherwise healthySubcutaneousCagrilintide 0.16, 0.30, 0.60, 1.2, 2.4 or 4.5 mg, each with semaglutide 2.4 mgOnce weekly, both drugs stepped up together every 4 weeks16 weeks of escalation, 4 weeks at target, 5 weeks follow-upPublished human clinical trial (Tier 1)[5]
Phase 2 monotherapy (NCT03856047)906 adults without diabetes (706 on cagrilintide)Subcutaneous, self-injected0.3, 0.6, 1.2, 2.4 or 4.5 mg. Comparators: liraglutide 3.0 mg daily, placeboOnce weekly26 weeks including up to 6 weeks of escalation, then 6 weeks off treatmentPublished human clinical trial (Tier 1)[1]
CagriSema phase 2, type 2 diabetes (NCT04982575)92 adults with type 2 diabetes, BMI 27 or higherSubcutaneousCagrilintide 2.4 mg alone, semaglutide 2.4 mg alone, or both at 2.4 mgOnce weekly32 weeksPublished human clinical trial (Tier 1)[6]
REDEFINE 1 (NCT05567796)3,417 adults, no diabetesSubcutaneousCagrilintide 2.4 mg alone (302 people), semaglutide 2.4 mg alone, both at 2.4 mg, or placeboOnce weekly68 weeksPublished human clinical trial (Tier 1)[2]
REDEFINE 2 (NCT05394519)1,206 adults with type 2 diabetesSubcutaneousCagriSema 2.4/2.4 or placebo. No cagrilintide-alone armOnce weekly68 weeksPublished human clinical trial (Tier 1)[7]
REIMAGINE 1 and 3 (type 2 diabetes)189 adults on diet and exercise; 274 adults on basal (long-acting) insulinSubcutaneousCagriSema 1.0/1.0 and 2.4/2.4, with matched placeboOnce weekly40 weeksPublished human clinical trial (Tier 1)[8][9]
REIMAGINE 2 (NCT06065540)2,713 adults with type 2 diabetes on metformin, with or without an SGLT2 inhibitor (a diabetes pill class)SubcutaneousCagrilintide 2.4 mg alone (152 people), CagriSema 2.4/2.4 and 1.0/1.0, semaglutide 2.4 and 1.0 mg, placeboOnce weekly68 weeksPublished human clinical trial (Tier 1)[10]
Other CagriSema phase 3 trialsREDEFINE 3, 4, 8, 11 and REIMAGINE 4; REDEFINE 9SubcutaneousMostly 2.4/2.4. REDEFINE 9 tests 1.0/1.0 and 1.7/1.7. A high-dose phase 3 tests 2.4/7.2Once weekly68 to 104 weeks, or event-drivenRegistered trials, company-reported results[11][12]
RENEW 1 and RENEW 2 (cagrilintide alone, phase 3)300 adults with obesity; 330 with obesity and type 2 diabetes (planned)Not stated in the registry recordNot disclosed in the registry recordNot stated in the registry recordPrimary endpoint at week 64Registered human trials, ongoing (Tier 2)[13][14]
Pramlintide, the older amylin drug (not cagrilintide)Adults with type 1 or type 2 diabetes using mealtime insulinSubcutaneousType 1: 15 mcg start, up to 60 mcg. Type 2: 60 mcg start, up to 120 mcg. Micrograms, not milligramsImmediately before each major mealOngoingPrescribing information (label)[15]
Gray-market “research” vialsSelf-directed adultsSubcutaneous, after reconstitution5 mg and 10 mg vials. Weekly amounts reported from 0.125 mg to 2.4 mg, with 4.5 mg asked aboutWeekly on most sites; 2 to 3 times weekly in one newsletterCycles of 16, 20, 26 to 32 or 68 weeks proposedCommunity, vendor or clinic reported (Tier 6); conflicting reports[16][17][18]
Practitioner or clinic protocolNot applicableNot applicableNot consistently reportedNot consistently reportedNot consistently reportedNo established or reliably sourced dosing information was identified

Phase 3 trial sizes marked planned are registry targets. The CagriSema rows are listed because cagrilintide is half of every arm, not because the fixed combination tells you what cagrilintide does alone.

Where these figures come from

Every milligram amount in the first six rows traces to a peer-reviewed paper from Novo Nordisk, and the registry rows trace to ClinicalTrials.gov. The gray-market rows are a different story, so here is the plain version.

  • Most-reported figures: 0.3 to 4.5 mg weekly (the phase 2 range), 10.8% (the 4.5 mg weight loss), and 2.4 mg (the amount in CagriSema).[1][2]
  • Origin: all of it is sponsor data. Novo Nordisk funded every published trial listed here, and Novo employees are authors on each.[1][5][6][2]
  • Human evidence: yes, for 0.3 to 4.5 mg weekly over 26 weeks and for 2.4 mg weekly over 68 weeks. Nothing is published yet for the cagrilintide-alone phase 3 program.
  • Animal evidence: rat studies exist, but their abstracts give no usable amounts, and animal amounts do not convert to human ones. None is shown here.
  • Practitioner figures: none identified.
  • Community figures: several sites publish weekly ranges and step ladders, and they disagree with each other. See the community section.
  • Websites repeating each other: the 0.25, 0.5, 1.0, 1.7 and 2.4 mg ladder with four weeks per step shows up on several community pages. It matches the semaglutide and CagriSema step schedule, which one of those pages says outright, and not any published cagrilintide-alone schedule.[19] The phase 2 monotherapy trial started at 0.6 mg (0.3 mg for the lowest group) and stepped up every 2 weeks.[1][16][20] Treat the ladder as one borrowed idea repeated many times, not many confirmations. At least one page also lists the wrong registry number for REDEFINE 1.
  • Weight-based dosing: none. Every trial amount is a fixed number of milligrams, not milligrams per kilogram.
  • Quoted weight loss: the often-quoted 22.7% belongs to CagriSema (both drugs) in REDEFINE 1. Cagrilintide alone lost 11.8% in the same trial.[21]

Detailed human data

Phase 2 monotherapy: 0.3 to 4.5 mg once weekly

This is the only published trial that put several cagrilintide-alone doses side by side. It enrolled 706 adults on cagrilintide, who had obesity, or overweight plus high blood pressure or abnormal blood fats, and no diabetes. They were randomized 6 to 1 to one of five weekly doses, daily liraglutide 3.0 mg, or placebo (99 and 101 people in the last two groups, with six placebo groups pooled). Participants injected themselves under the skin for 26 weeks, including up to 6 weeks of escalation, then stayed off treatment for 6 weeks.[1]

The 0.3 mg group started at 0.3 mg a week. Every other group started at 0.6 mg a week. Doses then rose every 2 weeks until each group reached its assigned amount, and the 4.5 mg group got there at week 6.[1]

Swipe the table sideways to see every column.

Phase 2 results at week 26 by weekly dose
Weekly doseWeight change, trial product estimand (SE)Difference vs placebo, trial product (95% CI)Difference vs placebo, treatment policy (95% CI)NauseaAny GI eventStopped for an adverse event
0.3 mg-6.0% (0.6)-3.0 (-4.6 to -1.4)-3.26 (-4.77 to -1.75)20%41%2%
0.6 mg-6.8% (0.6)-3.8 (-5.4 to -2.2)-4.01 (-5.52 to -2.50)27%45%4%
1.2 mg-9.1% (0.7)-6.1 (-7.8 to -4.4)-5.62 (-7.13 to -4.11)36%48%6%
2.4 mg-9.7% (0.6)-6.7 (-8.3 to -5.1)-6.64 (-8.15 to -5.14)31%51%6%
4.5 mg-10.8% (0.6)-7.8 (-9.4 to -6.2)-7.74 (-9.25 to -6.23)47%63%1%
Liraglutide 3.0 mg daily-9.0% (0.6)-6.0 (-7.6 to -4.4)-5.53 (-7.05 to -4.01)39%60%7%
Placebo (pooled)-3.0% (0.6)not applicablenot applicable18%32%3%

Source: the published paper and its accepted manuscript.[1] Differences are percentage points. Arm-level treatment policy means are shown only in a figure, so this table gives that estimand as differences from placebo. The paper’s text gives 2% to 6% for stopping on cagrilintide while its safety table shows 1% at 4.5 mg.

Mean weight loss at week 26 by weekly cagrilintide dose in the phase 2 trialBar chart, trial product estimand. Mean percent weight loss at week 26: 6.0 percent at 0.3 mg weekly, 6.8 at 0.6 mg, 9.1 at 1.2 mg, 9.7 at 2.4 mg, 10.8 at 4.5 mg, 9.0 with daily liraglutide 3.0 mg, and 3.0 with pooled placebo.0%2%4%6%8%10%12%Mean weight loss at week 266.0%0.3 mg6.8%0.6 mg9.1%1.2 mg9.7%2.4 mg10.8%4.5 mg9.0%Liraglutide3.0 mg daily3.0%PlaceboCagrilintide doses (light blue) are once weekly. Trial product estimand.
Week 26 mean weight loss by weekly cagrilintide dose, trial product estimand, from the published paper.[1] Liraglutide is a daily injection. Not a recommendation of any dose.

What the dose response shows

Weight loss climbs from 6.0% at 0.3 mg to 9.1% at 1.2 mg, then flattens: 9.7% at 2.4 mg and 10.8% at 4.5 mg. Going from 2.4 to 4.5 mg bought about one more percentage point, while nausea rose from 31% to 47% and any stomach or gut event from 51% to 63%.[1] The confidence intervals for 1.2, 2.4 and 4.5 mg overlap heavily, and each group had about 100 people, so gaps between neighboring doses are not reliable.

Two comparisons stand out. At 4.5 mg, cagrilintide beat daily liraglutide 3.0 mg by 1.8 points (10.8% vs 9.0%, p=0.03). At 2.4 mg it did not separate from liraglutide (difference 0.7 points, 95% CI -2.3 to 0.9).[1] No source checked for this page says why Novo chose 2.4 mg for CagriSema. A curve that flattens near 1.2 to 2.4 mg, plus the nausea at 4.5 mg, is at least consistent with a middle dose.

REDEFINE 1: cagrilintide alone at 2.4 mg for 68 weeks

REDEFINE 1 is the large phase 3 trial of CagriSema, and it included a cagrilintide-alone arm. It randomized 3,417 adults without diabetes 21:3:3:7 to CagriSema 2.4/2.4 (2,108 people), semaglutide 2.4 mg (302), cagrilintide 2.4 mg (302) or placebo (705), all once weekly with lifestyle support.[2] The paper’s primary analysis used the treatment policy estimand. Novo’s announcements gave both.

Swipe the table sideways to see every column.

REDEFINE 1 weight change at week 68
Arm (weekly)PeopleTrial product estimandTreatment policy estimand
CagriSema 2.4/2.4 mg2,108-22.7%-20.4%
Semaglutide 2.4 mg302-16.1%-14.9%
Cagrilintide 2.4 mg302-11.8%-11.5%
Placebo705-2.3%-3.0%

Sources: the NEJM paper for the 20.4% and 3.0% treatment policy figures and the arm sizes,[2] and Novo Nordisk’s announcements for the rest.[21][22] Weight loss of 15% or more occurred in 31.6% of the cagrilintide arm vs 4.7% on placebo (trial product) and 31.0% vs 5.2% (treatment policy).[22]

Read plainly: cagrilintide alone lost about half what CagriSema lost and less than semaglutide alone in the same trial. The combination beat semaglutide alone by 6.6 points on the trial product estimand and 5.5 on treatment policy (subtraction from the table). Dosing in this trial was flexible. People could stay on the target amount or step down, and at week 68, 57.3% of the CagriSema arm was on the top dose.[21] Healio reported 82.5% of the cagrilintide arm and 70.2% of the semaglutide arm on theirs.[23] Nausea led to stopping cagrilintide in 1.0% of that arm vs 0.1% on placebo.[22]

Phase 1b and the CagriSema phase 2

The phase 1b trial gave cagrilintide with semaglutide 2.4 mg in six sequential cohorts, with 11 or 12 people on cagrilintide in each (randomized 3:1 against placebo plus semaglutide), co-escalating both drugs in 4-week steps over 16 weeks, then 4 weeks at target. Cagrilintide’s half-life was 159 to 195 hours (about 6.6 to 8.1 days) across doses, which fits weekly dosing.[5] The abstract reports weight change only for the 1.2, 2.4 and 4.5 mg groups.

Swipe the table sideways to see every column.

Phase 1b weight change at week 20, all with semaglutide 2.4 mg weekly
Cagrilintide doseMean weight change (SE)Comparison
1.2 mg-15.7% (1.6)Pooled placebo cohorts 1 to 5: -9.8% (1.2)
2.4 mg-17.1% (1.5)Pooled placebo cohorts 1 to 5: -9.8% (1.2)
4.5 mg-15.4% (1.3)Matched placebo: -8.0% (2.2)

Source: published abstract.[5] Groups were small, and the 4.5 mg arm did no better than 2.4 mg.

The CagriSema phase 2 in type 2 diabetes randomized 92 adults 1:1:1 to CagriSema, semaglutide or cagrilintide, all escalated to 2.4 mg, for 32 weeks. Weight fell 15.6% on CagriSema, 5.1% on semaglutide and 8.1% on cagrilintide alone. HbA1c (average blood sugar over about three months) fell 2.2, 1.8 and 0.9 percentage points.[6]

Type 2 diabetes trials and the lower CagriSema doses

Because the REIMAGINE trials ran CagriSema at 1.0/1.0 as well as 2.4/2.4, they are the best evidence on whether the top dose is needed. REIMAGINE 1 (40 weeks, early type 2 diabetes) found HbA1c down 1.8 points at 2.4/2.4 and 1.5 at 1.0/1.0 vs 0.1 on placebo (efficacy estimand), with weight down 13.8% and 11.8% vs 1.4%.[8] REIMAGINE 3 (40 weeks, on basal insulin) found HbA1c down 2.33 and 2.10 points vs 0.66 on placebo.[9]

Swipe the table sideways to see every column.

CagriSema in type 2 diabetes: amounts and reported results
TrialAmounts (weekly)WeeksReported result
REDEFINE 2CagriSema 2.4/2.4 vs placebo68Weight -13.7% vs -3.4% (treatment policy). HbA1c 6.5% or lower in 73.5% vs 15.9%[7]
REIMAGINE 1CagriSema 2.4/2.4 and 1.0/1.0 vs placebo40HbA1c -1.8 and -1.5 vs -0.1 points (efficacy estimand)[8]
REIMAGINE 2CagriSema 2.4/2.4 and 1.0/1.0; semaglutide 2.4 and 1.0 mg; cagrilintide 2.4 mg; placebo68HbA1c -1.91 vs -1.75 for semaglutide 2.4 mg (efficacy estimand). Company-reported weight: -14.2% vs -10.2% vs -1.5% placebo. The cagrilintide-alone arm’s results were not in the abstract or the company announcement[10][24]
REIMAGINE 3CagriSema 2.4/2.4 and 1.0/1.0 vs placebo, added to basal insulin40HbA1c -2.33 and -2.10 vs -0.66 points (efficacy estimand)[9]
REIMAGINE 4CagriSema 2.4/2.4 vs tirzepatide 15 mg, open label68On-treatment analysis: weight -15.2% vs -15.8%, HbA1c -1.9 vs -2.2 points. Non-inferior (not meaningfully worse) for weight, not for HbA1c (company report)[12]

In obesity, REDEFINE 4 compared CagriSema 2.4/2.4 with tirzepatide 15 mg for 84 weeks in 809 adults. It missed its non-inferiority goal for weight loss: 23.0% vs 25.5% if everyone adhered, and 20.2% vs 23.6% on the treatment-regimen estimand, which counts everyone including those who stopped.[11] REDEFINE 9 tested 1.0/1.0 and 1.7/1.7 against placebo for 68 weeks and reported both superior, with figures promised at a later conference.[12]

Cagrilintide alone in phase 3: RENEW

Novo announced a dedicated cagrilintide program called RENEW in September 2025.[22] Two trials are registered, both randomized 2 to 1 for cagrilintide against placebo, both with percent weight change at week 64 as the primary endpoint. Neither registry record states the cagrilintide amount.[13][14]

Swipe the table sideways to see every column.

Registered cagrilintide-alone phase 3 and presentation trials
TrialPopulationPlanned peopleAmountRegistry status
RENEW 1 (NCT07220642)Obesity or overweight, no diabetes300Not disclosed in the registry recordActive, not recruiting; primary completion 11 May 2027[13]
RENEW 2 (NCT07220759)Obesity or overweight with type 2 diabetes330Not disclosed in the registry recordActive, not recruiting; primary completion 12 May 2027[14]
Two-presentation comparability (NCT07745504)Overweight or obesity285Not disclosed in the registry recordRecruiting; started August 2026[25]
GLP-1 stomach intolerance feasibility (NCT07607587)People who stopped a GLP-1 drug for GI side effects114Not disclosed in the registry recordPhase 1, recruiting[26]

Registry targets, not completed enrollment. No results are posted for any of these.

Pramlintide, the older amylin drug

Pramlintide (Symlin) is the one amylin drug with a label. It is approved only for adults with diabetes who use mealtime insulin. The label starts type 1 patients at 15 mcg and type 2 patients at 60 mcg, injected under the skin immediately before each major meal, with steps up to 60 mcg and 120 mcg respectively once nausea settles, and it cuts the mealtime insulin dose by half at the start.[15] Those are micrograms, and cagrilintide’s are milligrams. Different molecules, so the numbers cannot be compared. In one 24-week trial in 244 adults with obesity and no diabetes, pramlintide alone at 120 mcg three times daily produced 3.7% weight loss vs 2.2% on placebo, in a single-blind design that also tested add-on pills.[27] Its developers describe pramlintide as needing three daily injections because of a short half-life, which is the problem a long-acting analogue was built to fix.[4] Our pramlintide entry has the full picture.

Animal research amounts

Published rat studies of CagriSema and of cagrilintide with retatrutide exist, but the abstracts do not state the amounts given. Animal amounts are set per kilogram of animal body weight and do not convert to human amounts, so none is shown or implied here.

Swipe the table sideways to see every column.

Animal studies found, with the amount reported in each abstract
StudySpecies and designAmount in abstractFinding
Mol Metab, October 2026[28]Male diet-induced obese rats; CagriSema vs vehicle vs calorie-restricted groups; 6 weeks of treatment, 4 weeks after stoppingNot statedLower food intake explained 86% of the weight loss; weight came back after stopping
Nat Metab, September 2026[29]Male diet-induced obese rats; daily cagrilintide with retatrutideNot statedDose-dependent reductions in weight and food intake beyond single drugs

Practitioner and community-reported protocols

People search for these numbers, so here they are, with the source type on every line. None of this is clinical evidence. No practitioner or clinic protocol with an identifiable source turned up, so every row below is a community information site, a newsletter or a forum.

Swipe the table sideways to see every column.

Community-reported cagrilintide amounts, as each source states them
SourceSource typeAmounts reportedSchedule and durationVial and water as stated
Peptide Protocol Wiki calculatorsInformation site, unsignedChart of 0.15, 0.3 (“baseline”), 0.45 and 0.6 mg (“upper range”); “research range” 0.3 to 4.5 mg[17][30]Start 0.25 mg, escalate every 4 weeks over 16 to 20 weeks[17]5 mg or 10 mg vial, 2 mL as default
Peptide Dosing ProtocolsInformation site, one named author0.25, 0.5, 1.0, 1.7, 2.4 mg weekly. An FAQ says monotherapy is “commonly initiated at 0.6 mg per week”[16]4 weeks per step, 2.4 mg from week 17. Cycles: 16 weeks, 26 to 32 weeks, or 68 weeks5 mg with 2 or 3 mL; 10 mg with 2 or 3 mL
MyPeptideMatchInformation site, editorial teamSame 0.25 to 2.4 mg ladder[20]20 weeks on, 8 weeks off10 mg with 2 mL
PeptidesExplorerInformation site, pseudonymous authorWorked examples at 0.3, 0.6, 1.2 and 2.4 mg only; no schedule[31]Says its 28-day use limit is a convention, not a tested window5 mg with 1, 2 or 2.5 mL; 10 mg with 2, 3 or 4 mL
Hunter’s Health Hacks, July 2025Newsletter with affiliate linksStart 0.25 mg, then add 0.25 mg a week or raise slightly[32]2 to 3 times per week5 mg with 2 mL; 0.1 mL (10 units) equals 0.25 mg
Hunter’s Health Hacks, May 2025Newsletter, author’s own use0.5 to 1 mg per week, “multiple times over many weeks”[33]Uses a vial “within a month”5 mg or 10 mg with 2 mL
r/cagrilintideReddit forum postsStarting doses of 0.125 or 0.25 mg; 0.3, 0.5, 0.7 and 1 mg mentioned; one user on 2 mg says they feel “nothing” and asks about 4.5 mg[18]Mostly weekly; one user splits a weekly total across two days10 mg with 3 mL is the most common suggestion

Page labels and dates are as shown on each source. None of these sources cites a cagrilintide-alone trial for its step ladder.

Three things stand out. The sites disagree with each other on the start (0.125, 0.25 or 0.6 mg) and on the ceiling (0.6, 2.4 or 4.5 mg). One page says its default is “Clinical Trial-Based Protocol (20 community reports)” while its own community page counts one protocol. And one site’s own storage note says cagrilintide comes as a ready-to-use pen needing no reconstitution, beside a calculator that assumes a reconstituted vial.[17][19]

Reconstitution examples, exactly as sources state them

The same vial gives very different concentrations depending on how much water a source suggests. These figures are the sources’ own, not calculations from this page. Our reconstitution guide, the units guide and the reconstitution calculator explain the math without presets.

Swipe the table sideways to see every column.

Reconstitution examples quoted by community sources
SourceVialBacteriostatic waterConcentration statedWorked example stated
Peptide Protocol Wiki5 mg1 mL or 2 mL5.00 or 2.50 mg/mL300 mcg is 6 units or 12 units[17]
Peptide Protocol Wiki10 mg1 mL or 2 mL10.00 or 5.00 mg/mL300 mcg is 3 units or 6 units[30]
Peptide Dosing Protocols5 mg2 mL or 3 mL2.5 or 1.67 mg/mL2.4 mg is 96 units, or 144 units, which the page notes exceeds a 1 mL syringe[16]
Peptide Dosing Protocols10 mg2 mL or 3 mL5.0 or 3.33 mg/mL2.4 mg is 48 units or 72 units[16]
PeptidesExplorer5 mg; 10 mg1, 2 or 2.5 mL; 2, 3 or 4 mL5, 2.5 or 2 mg/mL; 5, 3.33 or 2.5 mg/mL0.6 mg is 12, 24 or 30 units at 5, 2.5 and 2 mg/mL[31]
MyPeptideMatch10 mg2 mL5 mg/mL0.25 mg is 5 units; 1 unit is 50 mcg[20]

Notice that “2 mL” is the default for both vial sizes on one site, which makes the 10 mg vial twice as concentrated as the 5 mg vial. A dose written as “units” is meaningless without the concentration beside it. Quoted storage windows (28 days after mixing is the common figure) come from convention on these pages, and one says so outright.[31]

Pearl white vase glowing with golden light surrounded by drifting jellyfish in a deep teal ocean

Escalation, timing, duration and routes

Swipe the table sideways to see every column.

How dose escalation is reported
SourceEscalation reportedEvidence category
Phase 2 monotherapyStart 0.6 mg (0.3 mg for the lowest group), increase every 2 weeks to the assigned dose; 4.5 mg reached at week 6Published human trial[1]
Phase 1b with semaglutideBoth drugs raised together in 4-week steps over 16 weeks, then 4 weeks at targetPublished human trial[5]
REDEFINE 1 CagriSemaHealth media list 0.25/0.25, 0.5/0.5, 1.0/1.0, 1.7/1.7 then 2.4/2.4, four weeks each, from week 17. not confirmed against the NEJM full textSecondary source[34]
RENEW 1 and 2Not disclosed in the registry recordRegistry[13][14]
Community ladders0.25 to 2.4 mg in 4-week steps (borrowed from CagriSema); 0.125 or 0.25 mg starts on forumsCommunity reported (Tier 6)[16][18]

Timing. Every trial dosed once a week. The half-life of 159 to 195 hours fits that, and it is the reason a 2-to-3-times-weekly plan in one newsletter has no published support.[5][32] A forum post that cites a half-life near 5 days also conflicts with the published figure.[18] None of the papers specifies a day of the week or a relation to meals.

Route. Subcutaneous injection in every trial. The REDEFINE 1 registry record says the injection goes in with a thin needle, typically in the stomach, thighs or upper arms.[35]

Duration. Trials ran 20 weeks (phase 1b), 26, 32, 40, 68 and 84 weeks. The community cycle lengths of 16, 20 on and 8 off, 26 to 32 and 68 weeks come from the sites themselves with no cited cagrilintide trial, and the 68-week one only mirrors a trial length.[16][20] What happens after stopping has been studied in rats, where weight came back.[28] The REDEFINE 1 registry record describes a two-year extension off treatment, and no results for it turned up.[35]

Combinations and stacks

  • Formally studied: cagrilintide with semaglutide at matched amounts (CagriSema), first as two separate injections in phase 1b and later as one fixed-dose product in phase 3.[5][2] A phase 1 trial is also testing cagrilintide with a GIP receptor agonist for stomach tolerability.[36]
  • Plausible on mechanism: cagrilintide with retatrutide, which has only rat data so far.[29] Our retatrutide entry covers that drug.
  • Practitioner reported: none identified.
  • Community reported: “stacks” of vial cagrilintide with semaglutide or tirzepatide. One site’s separate-vial CagriSema page lists 0.25 mg to 2.4 mg of each, injected on the same day with a separate syringe for each.[37] On Reddit, one user reported tirzepatide 15 mg alongside cagrilintide 1 mg on one day and 0.5 mg on another, and another described cagrilintide 0.25 mg with semaglutide 0.5 mg.[18] Another site calls a do-it-yourself CagriSema stack “not recommended” because it does not replicate the fixed-dose product, and says there is no trial data for cagrilintide with tirzepatide.[38][20]

Even the studied combination does not carry over. Novo is running separate trials to compare two presentations of cagrilintide, which suggests a change of formulation is not treated as interchangeable.[25] A vial of unknown powder mixed at home is a third thing again. For how the two drugs sit side by side, see the CagriSema entry, the semaglutide entry and ELR’s eloralintide vs cagrilintide comparison.

Side effects, quality and sourcing risks as reported

In trials. The common problems are stomach and gut events. In phase 2, nausea ran from 20% to 47% by dose against 18% on placebo, and any stomach or gut event from 41% to 63% against 32%. Administration-site reactions were also frequent.[1] In REDEFINE 1, stomach and gut events were mostly mild to moderate and eased over time.[22] BioSpace, citing analysts, reported injection-site reactions in 17% of cagrilintide-alone participants vs 2.6% on semaglutide alone, mainly attributed to cagrilintide.[39] The combination arm of REDEFINE 1 had stomach and gut events in 79.6% vs 39.9% on placebo.[2] Our GLP-1 and obesity peptides hub links the wider class.

In the community. Forum posts describe fatigue, dry mouth, loss of appetite, dehydration, strong hunger on stopping, injection pain, and one person who took 1 mg by accident and lost weight mostly as water over six days.[18] One newsletter says some people report “a kind of emotional flatness.”[32] These are anecdotes, not rates.

Independent testing of gray-market vials. The most useful data comes from Finnrick, a third-party service that publishes tests of peptides sent in by the public and tested in commercial labs. For cagrilintide, its aggregate page lists about 130 samples from about 20 sellers, tested between April 2025 and July 2026. Purity typically ranged from 94.45% to 99.94% (5th to 95th percentile). The measured amount of peptide typically differed from the advertised amount by as much as 48% (95th percentile), and in the seven most recent tests by anything from 18.4% under to 26.0% over. Two of the rated sellers got the lowest grade, “Fraud.”[40] The page’s own counts do not add up exactly (headline totals differ from the table), so treat the figures as approximate. It does not state endotoxin or sterility results in the page text reviewed. Our COA guide explains what a certificate does and does not prove.

Unvalidated tinkering. One newsletter proposes adjusting the pH of a reconstituted vial with a dilute acid, and cites no data, no lab and no study.[33] The only “purity” figure in another newsletter is a seller’s listing title. A forum user asks whether a 97% batch is acceptable. There is no standard to answer from.[32][18]

The practical reading: a 5 mg or 10 mg vial labeled cagrilintide may contain more or less peptide than the label says, and the trial doses above were sponsor-manufactured product, not a research-chemical vial. Questions about water type are covered in our bacteriostatic vs sterile water guide.

Regulatory and development status

  • Cagrilintide alone: not approved in any country. It is investigational in the RENEW phase 3 program.[13][14] The FDA states that cagrilintide cannot be used in compounding under federal law because it is not a component of any FDA-approved drug.[41]
  • CagriSema: Novo Nordisk submitted it to the FDA in December 2025 for weight management, based on REDEFINE 1 and REDEFINE 2.[11][42] Novo’s August 2026 report lists a US decision for the fourth quarter of 2026.[12] As of 2 November 2026, no approval announcement and no public PDUFA date (the FDA’s target decision date) turned up in the sources checked.[34] The Weight Loss Atlas tracks the filing on its CagriSema page.
  • Other regions: the Novo reports checked do not describe submissions outside the US.
  • Setbacks and open trials: REDEFINE 4 missed non-inferiority against tirzepatide on weight loss.[11] A cardiovascular outcomes trial of CagriSema (REDEFINE 3, 7,076 people randomized) is still running.[43]

The Weight Loss Atlas cagrilintide page and our clinical trial tracker follow status changes.

The combination of cagrilintide with semaglutide was tested at two lower doses (1.7/1.7 mg and 1.0/1.0 mg once weekly) in REDEFINE 9, reported by the manufacturer on 14 November 2026. This analysis of the lower-dose CagriSema trial sets out what the trial can and cannot say when the two doses are compared.

What is not public

  • The cagrilintide amount, escalation and device in the RENEW trials, and any RENEW results.
  • Per-dose side effects for cagrilintide alone beyond the 26-week phase 2 trial.
  • Published results for the cagrilintide-alone arms of REIMAGINE 2 and of the kidney disease and liver disease phase 2 trials (NCT06131372, NCT06409130); none were found.
  • Exposure data comparing a gray-market vial with trial product. None was found.
  • Any weight-based dosing, since all trials used fixed amounts.
  • A direct, matched-dose comparison of cagrilintide with newer amylin drugs. See the amylin drugs comparison and the petrelintide dosage guide for what each has published.

Frequently asked questions

What is the cagrilintide dosage?

There is no approved dosage. In the published phase 2 trial, adults received 0.3, 0.6, 1.2, 2.4 or 4.5 mg once weekly by subcutaneous injection for 26 weeks, and in REDEFINE 1 the cagrilintide-alone arm received 2.4 mg once weekly for 68 weeks. These are trial arms, not recommendations.

Is there a cagrilintide dosage chart?

The chart above lists every studied amount with its source. In short, weight loss at week 26 on the trial product estimand was 6.0% at 0.3 mg, 6.8% at 0.6 mg, 9.1% at 1.2 mg, 9.7% at 2.4 mg and 10.8% at 4.5 mg, against 3.0% on placebo. Community “dosage charts” are not trial schedules.

What is the cagrilintide weekly dose?

Every registered human trial dosed once weekly. The large trials used 2.4 mg a week. Phase 1b measured a half-life of 159 to 195 hours, which supports a weekly schedule.

What is the CagriSema dose?

CagriSema 2.4/2.4 means 2.4 mg of cagrilintide and 2.4 mg of semaglutide in one weekly injection. Lower strengths of 1.0/1.0 and 1.7/1.7 are in trials, and a 2.4/7.2 phase 3 is planned. It is not approved, so no label dose exists.

Cagrilintide vs semaglutide: which works better?

In REDEFINE 1, semaglutide 2.4 mg alone lost 16.1% of body weight and cagrilintide 2.4 mg alone lost 11.8% (trial product estimand), or 14.9% and 11.5% on treatment policy. The two together lost 22.7% and 20.4%. Semaglutide alone beat cagrilintide alone, and the pair beat either.

What is a cagrilintide 5 mg vial?

It is a research-chemical product sold outside any approval, in 5 mg and 10 mg sizes, that people reconstitute themselves. It is not the sponsor’s trial product, none of the trial figures on this page apply to it, and independent tests of such products found purity and amount that varied widely from the label. See the quality section above.

Is cagrilintide approved?

No. Cagrilintide alone is investigational. CagriSema was submitted to the FDA in December 2025, and Novo’s guidance is a decision in the fourth quarter of 2026. As of 2 November 2026, no approval has been announced in the sources checked.

What are the side effects of cagrilintide?

Mostly stomach and gut effects. In phase 2, nausea affected 20% to 47% of people by dose against 18% on placebo, and any stomach or gut event 41% to 63% against 32%. Injection-site reactions were also common. Long-term safety of cagrilintide alone is not yet known.

Can you combine cagrilintide with semaglutide or tirzepatide?

Cagrilintide with semaglutide at 2.4 mg each has been studied, as the fixed-dose CagriSema product. The first trial gave the two as separate injections of manufactured product, but home-mixed vials are not what any trial tested, and no trial data exists for cagrilintide with tirzepatide.

Pearl white vessel glowing gold on a teal seabed with golden jellyfish lanterns drifting around it

Bottom line

Cagrilintide is an amylin drug with one real dose-ranging trial behind it: 0.3 to 4.5 mg once weekly, where weight loss rose to about 9% by 1.2 mg and 10.8% at 4.5 mg, with more nausea at the top.[1] The strongest later evidence puts 2.4 mg weekly alone at 11.8% (trial product) over 68 weeks, behind semaglutide alone at 16.1% and well behind the pair at 22.7%.[21] What is merely reported: gray-market weekly ranges from 0.125 to 4.5 mg, step ladders borrowed from CagriSema, and vial recipes that disagree by a factor of two. What is speculative: any best dose for cagrilintide alone, since RENEW has not disclosed its amount. What is missing: RENEW results, per-dose safety beyond 26 weeks, and an FDA decision on CagriSema, which Novo expects in the fourth quarter of 2026.

Keep reading

Sources

  1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. Published 16 November 2021. https://doi.org/10.1016/S0140-6736(21)01751-7 Arm-level figures checked against the accepted manuscript: https://discovery.ucl.ac.uk/id/eprint/10155031/ Published human clinical trial (Tier 1). Funded by Novo Nordisk. PMID 34798060. NCT03856047.
  2. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. 2025;393(7):635-647. Published 22 June 2025. https://doi.org/10.1056/NEJMoa2502081 Published human clinical trial (Tier 1). Funded by Novo Nordisk. PMID 40544433. NCT05567796.
  3. Amylin analogs: the next major class of weight loss therapy: a review of experimental data and early-phase clinical trials. Diabetes Obes Metab. Published 14 July 2026. https://doi.org/10.1111/dom.71074 Narrative review. PMID 42452898. PMC13588232.
  4. Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. https://doi.org/10.1021/acs.jmedchem.1c00565 Medicinal chemistry paper by the developer. PMID 34288673.
  5. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. Published 22 April 2021. https://doi.org/10.1016/S0140-6736(21)00845-X Published human clinical trial (Tier 1). Funded by Novo Nordisk. PMID 33894838. NCT03600480.
  6. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. Published 23 June 2023. https://doi.org/10.1016/S0140-6736(23)01163-7 Published human clinical trial (Tier 1). Funded by Novo Nordisk. PMID 37364590. NCT04982575.
  7. Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med. 2025;393(7):648-659. Published 22 June 2025. https://doi.org/10.1056/NEJMoa2502082 Published human clinical trial (Tier 1). Funded by Novo Nordisk. PMID 40544432. NCT05394519.
  8. Aroda VR, Buzzetti R, Dalskov SM, et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1). Lancet Diabetes Endocrinol. 2026;14(8):649-661. Published 7 June 2026. https://doi.org/10.1016/S2213-8587(26)00126-9 Published human clinical trial (Tier 1). Funded by Novo Nordisk. PMID 42251860. NCT06323174.
  9. Rosenstock J, Billings LK, Gajria R, et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3). Lancet. 2026;408(10549):38-51. Published 7 June 2026. https://doi.org/10.1016/S0140-6736(26)01022-6 Published human clinical trial (Tier 1). Funded by Novo Nordisk. PMID 42251856. NCT06323161.
  10. Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2). Lancet Diabetes Endocrinol. 2026;14(8):662-677. Published 7 June 2026. https://doi.org/10.1016/S2213-8587(26)00125-7 Published human clinical trial (Tier 1). Funded by Novo Nordisk. PMID 42251859. NCT06065540.
  11. Novo Nordisk A/S. Form 6-K, financial report for 2025 (REDEFINE 4 results and US submission), dated 23 February 2026. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/353278/000117184326000996/f6k_022326.htm Company filing (sponsor-reported, not peer reviewed).
  12. Novo Nordisk A/S. Form 6-K, financial report for the first six months of 2026 (Company announcement No 48/2026), 4 August 2026. U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/0000353278/000035327826000023/caq22026.htm Company filing (sponsor-reported, not peer reviewed).
  13. ClinicalTrials.gov. NCT07220642: Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity (RENEW 1). Sponsor: Novo Nordisk. https://clinicaltrials.gov/study/NCT07220642 Trial registry record. Registered human trial (Tier 2). Active, not recruiting; no results.
  14. ClinicalTrials.gov. NCT07220759: Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes (RENEW 2). Sponsor: Novo Nordisk. https://clinicaltrials.gov/study/NCT07220759 Trial registry record. Registered human trial (Tier 2). Active, not recruiting; no results.
  15. Drugs.com. Pramlintide dosage (summary of the Symlin prescribing information). https://drugs.com/dosage/pramlintide.html; and PA Health & Wellness. Clinical policy: pramlintide (Symlin), v1.2026. https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/Pramlintide%20_Symlin_%20v1.2026.pdf Prescribing information as summarized by secondary sources. The FDA label itself was not opened.
  16. Grant G. Cagrilintide quick start. Peptide Dosing Protocols; page carries an October 2026 date. https://www.peptidedosingprotocols.com/protocol/cagrilintide Community information site, one named author (Tier 6).
  17. Peptide Protocol Wiki Team. Cagrilintide dosing calculator, reconstitution and units, 5 mg page. No publication date shown. https://www.peptideprotocolwiki.com/tools/dosing-calculator/cagrilintide-5mg Community information site, unsigned (Tier 6).
  18. Reddit. r/cagrilintide front page, about 25 recent posts, read on 2 November 2026 through a public Reddit mirror. Post ages are shown only as relative times, so individual posts cannot be dated. https://www.reddit.com/r/cagrilintide/ Community forum posts, anecdotal (Tier 6). Usernames omitted.
  19. Peptide Protocol Wiki Team. Cagrilintide dosing. Page dated 9 February 2026. https://www.peptideprotocolwiki.com/peptides/cagrilintide/dosing Community information site, unsigned (Tier 6). Its titration section carries no citation.
  20. MyPeptideMatch Editorial Team. Cagrilintide dosing, 10 mg vial protocol. Dated February 2026. https://www.mypeptidematch.com/protocols/cagrilintide-dosing-10mg Community information site (Tier 6).
  21. Novo Nordisk. CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. Company announcement, 20 December 2024 (copy distributed by BioSpace). https://www.biospace.com/press-releases/novo-nordisk-a-s-cagrisema-demonstrates-superior-weight-loss-in-adults-with-obesity-or-overweight-in-the-redefine-1-trial Company announcement (sponsor-reported, not peer reviewed).
  22. Novo Nordisk. Novo Nordisk presents phase 3 data for next generation amylin cagrilintide leading to advancement into dedicated clinical programme. Company announcement, 16 September 2025 (copy distributed by BioSpace). https://biospace.com/press-releases/novo-nordisk-presents-phase-3-data-for-next-generation-amylin-cagrilintide-leading-to-advancement-into-dedicated-clinical-programme Company announcement (sponsor-reported, not peer reviewed).
  23. Healio. Adults with obesity lost 22.7% of body weight with combination GLP-1/amylin analog. 14 February 2025. https://www.healio.com/news/endocrinology/20250214/adults-with-obesity-lost-227-of-body-weight-with-combination-glp1amylin-analog Trade press, secondary source. Used only for the share of each arm on the highest dose.
  24. Novo Nordisk. CagriSema demonstrated superior HbA1c reduction of 1.91 percentage points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial. Company announcement, 2 February 2026 (copy distributed by Inderes). https://www.inderes.dk/en/releases/novo-nordisk-as-cagrisema-demonstrated-superior-hba1c-reduction-of-191percent-points-and-weight-loss-of-142percent-in-adults-with-type-2-diabetes-in-the-reimagine-2-trial Company announcement (sponsor-reported, not peer reviewed).
  25. ClinicalTrials.gov. NCT07745504: A placebo-controlled comparability study to compare two presentations of cagrilintide for weight management in participants with overweight or obesity. Sponsor: Novo Nordisk. https://clinicaltrials.gov/study/NCT07745504 Trial registry record. Registered human trial (Tier 2). Recruiting.
  26. ClinicalTrials.gov. NCT07607587: Tolerability of cagrilintide in people with obesity that discontinued GLP-1-RA therapies due to gastrointestinal adverse events. Sponsor: Novo Nordisk. https://clinicaltrials.gov/study/NCT07607587 Trial registry record. Registered human trial (Tier 2). Phase 1, recruiting.
  27. Aronne LJ, Halseth AE, Burns CM, Miller S, Shen LZ. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial. Obesity. 2010;18(9):1739-1746. https://doi.org/10.1038/oby.2009.478 Published human clinical trial (Tier 1). PMID 20094043.
  28. Continued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats. Mol Metab. Published 28 October 2026. https://doi.org/10.1016/j.molmet.2026.102464 Published animal research (Tier 3). PMID 42951207.
  29. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nat Metab. Published 15 September 2026. https://doi.org/10.1038/s42255-026-01603-y Published animal research (Tier 3). PMID 42744908.
  30. Peptide Protocol Wiki Team. Cagrilintide dosing calculator, 10 mg page. No publication date shown. https://www.peptideprotocolwiki.com/tools/dosing-calculator/cagrilintide-10mg Community information site, unsigned (Tier 6).
  31. Doctor H. How to reconstitute cagrilintide (5 mg, 10 mg). PeptidesExplorer, 16 October 2026. https://peptidesexplorer.com/blog/how-to-reconstitute-cagrilintide Community information site, pseudonymous author (Tier 6).
  32. Williams H. New cagrilintide studies out. Hunter’s Health Hacks newsletter, 29 July 2025. https://huntershealthhacks.beehiiv.com/p/new-cagrilintide-studies-out-79070e625a312fd4 Newsletter with affiliate links and discount codes for a research-chemical seller (Tier 6).
  33. Williams H. The cagrilintide pH debate. Hunter’s Health Hacks newsletter, 14 May 2025. https://huntershealthhacks.beehiiv.com/p/the-cagrilinitde-ph-debate-b987135ecfd5a343 Newsletter, author’s own use and opinion, no data cited (Tier 6).
  34. Healthline. CagriSema: FDA status, results, and uses of the GLP-1 drug. Article dated 13 October 2026. https://www.healthline.com/health/drugs/cagrisema-for-weight-loss Consumer health media, secondary source. Lists the REDEFINE 1 step schedule; not the trial paper.
  35. ClinicalTrials.gov. NCT05567796: Efficacy and safety of cagrilintide 2.4 mg in combination with semaglutide 2.4 mg (CagriSema) once weekly in participants with overweight or obesity (REDEFINE 1). Sponsor: Novo Nordisk. https://clinicaltrials.gov/study/NCT05567796 Trial registry record. Registered human trial (Tier 2 as a record; results are in the NEJM paper). Active, not recruiting.
  36. ClinicalTrials.gov. NCT07411560: Single-centre study investigating the role of long-acting subcutaneous GIP receptor agonist in combination with long-acting subcutaneous amylin receptor agonist on gastrointestinal tolerability. Sponsor: Novo Nordisk. https://clinicaltrials.gov/study/NCT07411560 Trial registry record. Registered human trial (Tier 2). Phase 1, recruiting.
  37. Grant G. CagriSema dosing protocol: cagrilintide 2.4 mg + semaglutide 2.4 mg. Peptide Dosing Protocols. https://www.peptidedosingprotocols.com/stacks/cagrisema Community information site, one named author (Tier 6). Page shows two different dates, October 2026 and June 2026.
  38. Peptide Protocol Wiki Team. Cagrilintide community reports. Page dated 16 February 2026. https://www.peptideprotocolwiki.com/peptides/cagrilintide/community Community information site, unsigned (Tier 6). Cites Reddit r/Peptides and r/Semaglutide generally, no named threads.
  39. BioSpace. Novo’s amylin injectable cagrilintide hits 11.8% weight reduction in phase III trial. News report, 16 September 2025. https://www.biospace.com/drug-development/novos-amylin-injectable-cagrilintide-hits-11-8-weight-reduction-in-phase-iii-trial Trade press, secondary source. Injection-site figures are attributed there to analysts.
  40. Finnrick. Cagrilintide: independent test results across sellers (aggregate page, read through a public mirror host on 2 November 2026). https://www.finnrick.com/products/cagrilintide Third-party testing aggregator. Samples are submitted by the public and tested in commercial labs; methods are summarized on the site, not peer reviewed.
  41. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss (copy hosted by the Kentucky Board of Nursing, dated 5 September 2025 in its file name). https://kbn.ky.gov/KBN%20Documents/FDA%E2%80%99s%20Concerns%20with%20Unapproved%20GLP-1%20Drugs%20Used%20for%20Weight%20Loss%20_%209.5.25.pdf Regulator document.
  42. Patient Care Online. Novo Nordisk files NDA for CagriSema, novel GLP-1-amylin combination for chronic weight management. 18 December 2025. https://www.patientcareonline.com/view/novo-nordisk-files-nda-for-cagrisema-novel-glp-1-amylin-combination-for-chronic-weight-management Trade press report of a company announcement, secondary source.
  43. Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Am Heart J. Published 6 October 2026. https://doi.org/10.1016/j.ahj.2026.107626 Published trial design paper (Tier 2: no outcome data). PMID 42838477. NCT05669755.

Educational reference only, not medical advice. This page documents amounts studied in published and registered research and figures circulating online. It does not tell any reader what to take, and it does not say any amount is safe or effective. Talk to a qualified, licensed clinician about personal medical decisions.

Share thisFacebookXEmail
Image placeholder

PeptideBlog Editorial compiles and reviews published research, clinical trial data, and community-reported information on peptides so readers can see what is actually documented versus what is simply repeated online. Every entry is sourced and evidence-graded. This is educational content, not medical advice.